Cite
HARVARD Citation
Lombardi, G. et al. (2019). Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet oncology. 20 (1), pp. 110-119. [Online].